SODIUM CHLORIDE MONICO 0.45 %

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

SODIUM CHLORIDE

Disponible depuis:

RAZ PHARMACEUTICS LTD, ISRAEL

Code ATC:

B05XA03

forme pharmaceutique:

SOLUTION FOR INFUSION

Composition:

SODIUM CHLORIDE 0.45 G / 100 ML

Mode d'administration:

I.V

Type d'ordonnance:

Required

Fabriqué par:

MONICO S.P.A., ITALY

Domaine thérapeutique:

SODIUM CHLORIDE

indications thérapeutiques:

Supply of water and electrolytes.

Date de l'autorisation:

2020-03-15

Résumé des caractéristiques du produit

Testo:
Carattere
Helvetica Neue
Dimensione 8,0 PT
Interlinea
8,0 PT
Title
--
Subtitle
--
Codice:
RAZS3353-02
Data:
01/09/2021
Prodotto:
PRODOTTO: IS SODIUM CHLORIDE 0.45 % RAZ
Formato:
MM 297X210 - PIEGATO 148,5X210
Carta:
MECCANOGRAFICA SENZA LEGNO 50 G/MQ
Colori:
FUSTELLA
BLACK
The design and text are Monico SpA property - Monico© All rights
reserved
Esecuzione: GROWE srl - Vicenza
Sodium Chloride Monico 0.45% is a hypotonic
solution, with an approximate osmolarity of 154
mOsm/l.
The pharmacodynamic properties of the solution are
those of the sodium and chloride ions in maintaining
the fluid and electrolyte balance. Ions, such as
sodium, circulate through the cell membrane, using
various mechanisms of transport, among which is
the sodium pump (Na-K-ATPase). Sodium plays
an important role in neurotransmission, cardiac
electrophysiology and renal function.
Chloride is mainly an extracellular anion. Intracellular
chloride is in high concentration in red blood cells
and gastric mucosa. Reabsorption of chloride follows
reabsorption of sodium.
When medication is added to Sodium Chloride
Monico 0.45%, the overall pharmacodynamics of the
solution will depend on the nature of the medicinal
product used.
5.2 Pharmacokinetic properties
Sodium and Chloride are mainly distributed in blood
and extracellular compartments (Na
+
: 142 mmol/l –
Cl
-
: 103 mmol/l).
Sodium is predominantly excreted by the kidney with
a renal reabsorption. Small amounts of sodium are
lost in the faeces and sweat at the skin level.
When medication is added to Sodium Chloride
Monico 0.45%, the overall pharmacokinetics of the
solution will depend on the nature of the medicinal
product used.
5.3 Preclinical safety data
Preclinical safety data of this solution for infusion in
animals are not relevant since its constituents are
physiological components of animal and human
plasma.
Toxic effects are not to be expected under the
condition of clinical application. The safety of
potential additives should be considered separately.
6.
Pharmaceutical particu